[Development of tyrosine kinase inhibitors for hematologic neoplasms. FLT3 and JAK2 as therapeutic targets].
Lipka
Daniel
D
Medizinstudium an der Ruprecht-Karls-Universität Heidelberg.
Heidel
Florian
F
Huber
Christoph
C
Fischer
Thomas
T
D000818:Animals; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D006801:Humans; D053614:Janus Kinase 2 / Q000187:drug effects*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D051941:fms-Like Tyrosine Kinase 3 / Q000187:drug effects*
D047428:Protein Kinase Inhibitors; C497970:FLT3 protein, human; D011505:Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3; C507924:JAK2 protein, human; D053614:Janus Kinase 2